1. Altered type III collagen turnover measured in pre-treatment serum predicts outcome in metastatic melanoma patients treated with Ipilimumab. (March 2018) Authors: Jensen, C.; Madsen, D.; Hansen, M.; Schmidt, H.; Svane, I.; Karsdal, M.; Willumsen, N. Journal: European journal of cancer Issue: Volume 92(2018)Supplement 1 Page Start: S7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Exploring phenotypic and functional characteristics of cultured tumor infiltrating lymphocytes. (March 2018) Authors: Rana, M.; Borch, T.; Draghi, A.; Gokuldass, A.; Donia, M.; Svane, I. Journal: European journal of cancer Issue: Volume 92(2018)Supplement 1 Page Start: S24 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Tumor-specific immune responses after short-term BRAF-inhibitor induction in patients with melanoma resistant to checkpoint inhibitors. (March 2019) Authors: Gokuldass, A.; Borch, T.H.; Draghi, A.; Nielsen, M.; Kjeldsen, J.; Kverneland, A.; Lorentzen, C.; Met, O.; Donia, M.; Svane, I. Journal: European journal of cancer Issue: Volume 110(2019)Supplement 1 Page Start: S26 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗